ArticleOncoimmunology2012
Immunochemotherapy against colon cancer by gene transfer of interleukin-12 in combination with oxaliplatin.
Article in Oncoimmunology, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed, 10 citations in OpenAlex.
- An in silico exploration of combining Interleukin-12 with Oxaliplatin to treat liver-metastatic colorectal cancer.BMC cancer · 2020Article
- Immunostimulatory nanomedicines synergize with checkpoint blockade immunotherapy to eradicate colorectal tumors.Nature communications · 2019Article
- Improved anti-tumor efficacy via combination of oxaliplatin and fibrin glue in colorectal cancer.Oncotarget · 2018Article
- Chemo-immunotherapy with oxaliplatin and interleukin-7 inhibits colon cancer metastasis in mice.PloS one · 2014Article
- Trial Watch: DNA vaccines for cancer therapy.Oncoimmunology · 2014Review
- Trial watch: DNA vaccines for cancer therapy.Oncoimmunology · 2013Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Using a murine model of liver metastases, we found that oxaliplatin can enhance the immunostimulatory effect of interleukin-12 delivered by an adenoviral vector. A shift toward a favorable immune microenvironment was observed in tumors, with a relative increase in CD8+ T cells vs. T regulatory and myeloid-derived suppressor cells.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.